Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 82 | 2024 | 21162 | 2.520 |
Why?
|
Aspirin | 8 | 2024 | 3135 | 1.440 |
Why?
|
Receptors, Progesterone | 13 | 2024 | 1145 | 1.060 |
Why?
|
Estrogen Replacement Therapy | 7 | 2013 | 1209 | 0.810 |
Why?
|
Postmenopause | 14 | 2022 | 2518 | 0.800 |
Why?
|
Receptors, Estrogen | 14 | 2024 | 2247 | 0.740 |
Why?
|
Nurses | 14 | 2023 | 2494 | 0.720 |
Why?
|
Premenopause | 14 | 2018 | 1039 | 0.690 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 4 | 2024 | 2276 | 0.660 |
Why?
|
Carcinoma, Ductal, Breast | 5 | 2016 | 1094 | 0.640 |
Why?
|
Amino Acids, Essential | 1 | 2016 | 26 | 0.550 |
Why?
|
Dietary Proteins | 3 | 2016 | 960 | 0.470 |
Why?
|
Amino Acids, Branched-Chain | 1 | 2016 | 268 | 0.450 |
Why?
|
Hot Flashes | 1 | 2014 | 330 | 0.370 |
Why?
|
Alcohol Drinking | 6 | 2015 | 4049 | 0.360 |
Why?
|
Hormone Replacement Therapy | 2 | 2008 | 756 | 0.360 |
Why?
|
Aromatase Inhibitors | 2 | 2024 | 519 | 0.340 |
Why?
|
Uridine Diphosphate N-Acetylglucosamine | 1 | 2009 | 18 | 0.330 |
Why?
|
Streptococcus equi | 1 | 2009 | 9 | 0.330 |
Why?
|
Breast | 2 | 2017 | 1975 | 0.330 |
Why?
|
Melatonin | 1 | 2014 | 669 | 0.310 |
Why?
|
Risk Factors | 45 | 2022 | 74962 | 0.310 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2015 | 936 | 0.300 |
Why?
|
Dietary Fiber | 4 | 2016 | 767 | 0.300 |
Why?
|
Nutritional Status | 1 | 2016 | 1627 | 0.300 |
Why?
|
Female | 87 | 2024 | 397089 | 0.290 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2013 | 1244 | 0.280 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2024 | 3553 | 0.280 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2007 | 131 | 0.270 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2013 | 1517 | 0.260 |
Why?
|
Affect | 1 | 2014 | 1501 | 0.260 |
Why?
|
Receptor, erbB-2 | 7 | 2024 | 2588 | 0.260 |
Why?
|
Neoplasm Metastasis | 5 | 2021 | 4921 | 0.260 |
Why?
|
Hyaluronic Acid | 1 | 2009 | 487 | 0.250 |
Why?
|
Ethanol | 1 | 2011 | 1332 | 0.250 |
Why?
|
Endocrinology | 1 | 2011 | 443 | 0.240 |
Why?
|
Menopause, Premature | 1 | 2006 | 124 | 0.240 |
Why?
|
Proportional Hazards Models | 17 | 2020 | 12558 | 0.240 |
Why?
|
Fruit | 3 | 2020 | 1164 | 0.240 |
Why?
|
Vegetables | 3 | 2020 | 1198 | 0.240 |
Why?
|
Mammography | 1 | 2015 | 2434 | 0.240 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2014 | 1099 | 0.230 |
Why?
|
Carcinoma, Lobular | 3 | 2016 | 480 | 0.230 |
Why?
|
Gonadal Steroid Hormones | 1 | 2008 | 708 | 0.230 |
Why?
|
Feeding Behavior | 6 | 2018 | 3203 | 0.230 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2024 | 9433 | 0.220 |
Why?
|
Middle Aged | 51 | 2024 | 223491 | 0.210 |
Why?
|
Receptors, Calcitriol | 1 | 2005 | 361 | 0.210 |
Why?
|
Prospective Studies | 30 | 2023 | 54920 | 0.210 |
Why?
|
Dietary Fats | 4 | 2014 | 2003 | 0.210 |
Why?
|
Adult | 56 | 2024 | 223640 | 0.210 |
Why?
|
Central Nervous System Stimulants | 1 | 2011 | 1181 | 0.210 |
Why?
|
Risk Assessment | 18 | 2017 | 24318 | 0.210 |
Why?
|
Tamoxifen | 1 | 2007 | 968 | 0.200 |
Why?
|
Humans | 88 | 2024 | 768393 | 0.200 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2006 | 618 | 0.200 |
Why?
|
Acupuncture, Ear | 1 | 2022 | 13 | 0.200 |
Why?
|
Women's Health | 3 | 2020 | 2078 | 0.200 |
Why?
|
Ovary | 1 | 2006 | 960 | 0.190 |
Why?
|
Smoking | 6 | 2013 | 9111 | 0.190 |
Why?
|
Dietary Supplements | 2 | 2020 | 3443 | 0.190 |
Why?
|
Odds Ratio | 6 | 2016 | 9682 | 0.180 |
Why?
|
Meningeal Carcinomatosis | 1 | 2021 | 66 | 0.180 |
Why?
|
Nitriles | 2 | 2021 | 984 | 0.180 |
Why?
|
Early Detection of Cancer | 1 | 2015 | 3236 | 0.180 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2024 | 354 | 0.180 |
Why?
|
Estrogens | 4 | 2011 | 1534 | 0.180 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 11854 | 0.180 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2024 | 566 | 0.170 |
Why?
|
Carcinoma | 1 | 2011 | 2341 | 0.170 |
Why?
|
Incidence | 16 | 2018 | 21544 | 0.170 |
Why?
|
Hyperinsulinism | 1 | 2022 | 401 | 0.170 |
Why?
|
Genes, BRCA2 | 1 | 2002 | 592 | 0.160 |
Why?
|
Meat | 3 | 2014 | 588 | 0.160 |
Why?
|
Neoplasm Staging | 9 | 2020 | 11254 | 0.160 |
Why?
|
Fatigue | 2 | 2023 | 1555 | 0.160 |
Why?
|
Aged | 27 | 2024 | 171562 | 0.160 |
Why?
|
Genes, BRCA1 | 1 | 2002 | 755 | 0.160 |
Why?
|
Dietary Carbohydrates | 3 | 2020 | 896 | 0.160 |
Why?
|
Canada | 1 | 2024 | 2139 | 0.160 |
Why?
|
Triazoles | 1 | 2004 | 904 | 0.150 |
Why?
|
Disease-Free Survival | 3 | 2024 | 6856 | 0.150 |
Why?
|
Meningeal Neoplasms | 2 | 2021 | 1253 | 0.150 |
Why?
|
Diet | 7 | 2022 | 8090 | 0.140 |
Why?
|
Double-Blind Method | 3 | 2024 | 12456 | 0.140 |
Why?
|
Follow-Up Studies | 13 | 2024 | 39407 | 0.140 |
Why?
|
Multivariate Analysis | 8 | 2016 | 12092 | 0.140 |
Why?
|
Paclitaxel | 2 | 2022 | 1736 | 0.140 |
Why?
|
United States | 18 | 2024 | 73150 | 0.140 |
Why?
|
Administration, Oral | 1 | 2024 | 4039 | 0.130 |
Why?
|
Dairy Products | 2 | 2018 | 490 | 0.130 |
Why?
|
Cholecalciferol | 1 | 2020 | 557 | 0.130 |
Why?
|
Confidence Intervals | 5 | 2020 | 2931 | 0.120 |
Why?
|
Blood Platelets | 2 | 2019 | 2476 | 0.120 |
Why?
|
Leucine | 1 | 2016 | 548 | 0.120 |
Why?
|
Neoplasms, Hormone-Dependent | 2 | 2007 | 410 | 0.110 |
Why?
|
Survivors | 3 | 2014 | 2382 | 0.110 |
Why?
|
Glycemic Index | 3 | 2020 | 400 | 0.110 |
Why?
|
Survival Analysis | 6 | 2021 | 10117 | 0.110 |
Why?
|
Piperazines | 1 | 2024 | 2552 | 0.110 |
Why?
|
Fibrocystic Breast Disease | 1 | 2013 | 103 | 0.110 |
Why?
|
Enzyme Inhibitors | 1 | 2004 | 3722 | 0.110 |
Why?
|
Prognosis | 8 | 2022 | 30022 | 0.100 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2022 | 2884 | 0.100 |
Why?
|
Vitamins | 1 | 2020 | 1637 | 0.100 |
Why?
|
Pyridines | 1 | 2024 | 2889 | 0.100 |
Why?
|
Weight Gain | 2 | 2017 | 2356 | 0.100 |
Why?
|
Anti-Inflammatory Agents | 1 | 2021 | 1813 | 0.100 |
Why?
|
Models, Statistical | 4 | 2019 | 5099 | 0.100 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2012 | 16028 | 0.090 |
Why?
|
Echocardiography | 1 | 2023 | 5044 | 0.090 |
Why?
|
Menarche | 1 | 2013 | 538 | 0.090 |
Why?
|
Pyrazoles | 1 | 2021 | 2021 | 0.090 |
Why?
|
Dissent and Disputes | 1 | 2011 | 150 | 0.090 |
Why?
|
Mathematical Computing | 2 | 2007 | 142 | 0.090 |
Why?
|
Premature Birth | 1 | 2022 | 1814 | 0.080 |
Why?
|
Intracranial Embolism | 1 | 2011 | 189 | 0.080 |
Why?
|
Time Factors | 10 | 2017 | 40272 | 0.080 |
Why?
|
Nisin | 1 | 2009 | 4 | 0.080 |
Why?
|
Lactococcus lactis | 1 | 2009 | 28 | 0.080 |
Why?
|
Genetic Testing | 1 | 2002 | 3587 | 0.080 |
Why?
|
ABO Blood-Group System | 1 | 2012 | 381 | 0.080 |
Why?
|
Acrylamide | 1 | 2009 | 59 | 0.080 |
Why?
|
Cyclooxygenase 2 | 1 | 2011 | 599 | 0.080 |
Why?
|
Quinazolines | 2 | 2012 | 1373 | 0.080 |
Why?
|
Insulin Resistance | 1 | 2022 | 3981 | 0.080 |
Why?
|
Nausea | 2 | 2022 | 682 | 0.080 |
Why?
|
Glucuronosyltransferase | 1 | 2009 | 136 | 0.080 |
Why?
|
Antineoplastic Agents | 3 | 2011 | 13697 | 0.080 |
Why?
|
Microbiological Techniques | 1 | 2009 | 97 | 0.080 |
Why?
|
Research | 1 | 2017 | 1981 | 0.080 |
Why?
|
Operon | 1 | 2009 | 371 | 0.080 |
Why?
|
Endometriosis | 1 | 2016 | 875 | 0.080 |
Why?
|
Anticarcinogenic Agents | 1 | 2010 | 251 | 0.080 |
Why?
|
Age Factors | 7 | 2017 | 18471 | 0.070 |
Why?
|
Young Adult | 7 | 2024 | 60049 | 0.070 |
Why?
|
Cause of Death | 2 | 2020 | 3728 | 0.070 |
Why?
|
Disease Progression | 3 | 2024 | 13646 | 0.070 |
Why?
|
Life Style | 3 | 2008 | 3929 | 0.070 |
Why?
|
Endocarditis | 1 | 2011 | 352 | 0.070 |
Why?
|
Molecular Weight | 1 | 2009 | 2172 | 0.070 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2019 | 2763 | 0.070 |
Why?
|
Alanine | 1 | 2009 | 613 | 0.070 |
Why?
|
Carcinogens | 1 | 2009 | 455 | 0.070 |
Why?
|
Lymphatic Metastasis | 3 | 2011 | 2925 | 0.070 |
Why?
|
Diabetes, Gestational | 1 | 2016 | 1260 | 0.070 |
Why?
|
Glycine | 1 | 2009 | 672 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6541 | 0.060 |
Why?
|
Dihydroxycholecalciferols | 1 | 2005 | 17 | 0.060 |
Why?
|
Progesterone | 2 | 2017 | 751 | 0.060 |
Why?
|
Forecasting | 1 | 2015 | 2948 | 0.060 |
Why?
|
Case-Control Studies | 5 | 2016 | 22296 | 0.060 |
Why?
|
Vitamin D | 3 | 2018 | 3310 | 0.060 |
Why?
|
Energy Metabolism | 1 | 2016 | 2906 | 0.060 |
Why?
|
Physical Endurance | 1 | 2008 | 370 | 0.060 |
Why?
|
Genotype | 3 | 2012 | 13042 | 0.060 |
Why?
|
Counseling | 2 | 2004 | 1553 | 0.060 |
Why?
|
Physical Fitness | 1 | 2009 | 744 | 0.060 |
Why?
|
Nutrition Assessment | 2 | 2018 | 740 | 0.060 |
Why?
|
Laparoscopy | 1 | 2016 | 2056 | 0.060 |
Why?
|
Genital Neoplasms, Female | 1 | 2010 | 539 | 0.060 |
Why?
|
Acetaminophen | 1 | 2009 | 556 | 0.060 |
Why?
|
Adolescent | 10 | 2022 | 89184 | 0.060 |
Why?
|
Exercise | 3 | 2008 | 5946 | 0.060 |
Why?
|
Neoplasms | 2 | 2020 | 22385 | 0.060 |
Why?
|
Risk | 5 | 2016 | 9636 | 0.060 |
Why?
|
Aged, 80 and over | 5 | 2024 | 59686 | 0.060 |
Why?
|
Plasmids | 1 | 2009 | 2268 | 0.060 |
Why?
|
Energy Intake | 2 | 2022 | 2145 | 0.060 |
Why?
|
Piperidines | 1 | 2012 | 1659 | 0.060 |
Why?
|
Body Mass Index | 8 | 2015 | 13052 | 0.050 |
Why?
|
Muscle Strength | 1 | 2008 | 641 | 0.050 |
Why?
|
Gene Expression Regulation, Bacterial | 1 | 2009 | 1137 | 0.050 |
Why?
|
Decision Support Techniques | 1 | 2013 | 2006 | 0.050 |
Why?
|
Cyclophosphamide | 2 | 2022 | 2226 | 0.050 |
Why?
|
Environmental Monitoring | 1 | 2009 | 1463 | 0.050 |
Why?
|
Plant Oils | 1 | 2023 | 199 | 0.050 |
Why?
|
Neoplasm Invasiveness | 2 | 2016 | 3633 | 0.050 |
Why?
|
Parity | 2 | 2016 | 938 | 0.050 |
Why?
|
Consensus | 1 | 2011 | 3212 | 0.050 |
Why?
|
Sleep | 1 | 2017 | 4802 | 0.050 |
Why?
|
Anorexia | 1 | 2021 | 152 | 0.050 |
Why?
|
Hysterectomy | 1 | 2006 | 864 | 0.050 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 3252 | 0.050 |
Why?
|
Recurrence | 1 | 2013 | 8506 | 0.040 |
Why?
|
Body Weight | 3 | 2008 | 4629 | 0.040 |
Why?
|
Vitamin A | 1 | 2003 | 611 | 0.040 |
Why?
|
Carotenoids | 1 | 2003 | 620 | 0.040 |
Why?
|
Insulin | 2 | 2020 | 6607 | 0.040 |
Why?
|
Brain Neoplasms | 1 | 2021 | 9198 | 0.040 |
Why?
|
Ascorbic Acid | 1 | 2003 | 658 | 0.040 |
Why?
|
Obesity | 3 | 2020 | 13084 | 0.040 |
Why?
|
Hepatitis | 1 | 2021 | 228 | 0.040 |
Why?
|
Primary Prevention | 1 | 2007 | 1187 | 0.040 |
Why?
|
Motor Activity | 1 | 2009 | 2720 | 0.040 |
Why?
|
Genetic Vectors | 1 | 2009 | 3413 | 0.040 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2022 | 631 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2011 | 10776 | 0.040 |
Why?
|
Carboplatin | 1 | 2022 | 799 | 0.040 |
Why?
|
Radiotherapy Dosage | 1 | 2006 | 2922 | 0.040 |
Why?
|
Diet Records | 1 | 2020 | 426 | 0.040 |
Why?
|
Vitamin E | 1 | 2003 | 874 | 0.040 |
Why?
|
Longitudinal Studies | 4 | 2020 | 14784 | 0.040 |
Why?
|
Taxoids | 1 | 2022 | 668 | 0.040 |
Why?
|
Medical History Taking | 1 | 2002 | 776 | 0.040 |
Why?
|
Cohort Studies | 7 | 2022 | 41795 | 0.040 |
Why?
|
Sweetening Agents | 1 | 2021 | 290 | 0.040 |
Why?
|
Vomiting | 1 | 2022 | 655 | 0.040 |
Why?
|
Lactose | 1 | 2018 | 95 | 0.040 |
Why?
|
Quality of Life | 2 | 2014 | 13503 | 0.040 |
Why?
|
Health Surveys | 3 | 2017 | 4056 | 0.040 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 906 | 0.040 |
Why?
|
Exanthema | 1 | 2021 | 503 | 0.030 |
Why?
|
PTEN Phosphohydrolase | 1 | 2022 | 1119 | 0.030 |
Why?
|
Blood Glucose | 3 | 2020 | 6430 | 0.030 |
Why?
|
Folic Acid | 1 | 2003 | 1336 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2012 | 8634 | 0.030 |
Why?
|
Neovascularization, Pathologic | 2 | 2019 | 2635 | 0.030 |
Why?
|
Severity of Illness Index | 1 | 2013 | 15939 | 0.030 |
Why?
|
Testosterone | 1 | 2006 | 2493 | 0.030 |
Why?
|
Dyspnea | 1 | 2023 | 1351 | 0.030 |
Why?
|
Calcium, Dietary | 1 | 2018 | 533 | 0.030 |
Why?
|
Polymorphism, Genetic | 1 | 2005 | 4250 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2010 | 5336 | 0.030 |
Why?
|
Depression | 1 | 2014 | 8241 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2002 | 1885 | 0.030 |
Why?
|
Hematopoiesis | 1 | 2023 | 2058 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 2011 | 7453 | 0.030 |
Why?
|
Fever | 1 | 2021 | 1620 | 0.030 |
Why?
|
Environmental Exposure | 1 | 2009 | 4528 | 0.030 |
Why?
|
Endometrial Neoplasms | 1 | 2003 | 1382 | 0.030 |
Why?
|
Diagnosis, Differential | 2 | 2023 | 13020 | 0.030 |
Why?
|
Estrogen Receptor alpha | 1 | 2017 | 581 | 0.030 |
Why?
|
Colitis | 1 | 2021 | 1244 | 0.030 |
Why?
|
Platelet Factor 4 | 1 | 2012 | 132 | 0.020 |
Why?
|
Reproductive History | 1 | 2013 | 210 | 0.020 |
Why?
|
Colonic Neoplasms | 1 | 2004 | 2544 | 0.020 |
Why?
|
Biomarkers, Pharmacological | 1 | 2012 | 162 | 0.020 |
Why?
|
Nutrition Surveys | 1 | 2018 | 1736 | 0.020 |
Why?
|
Comorbidity | 2 | 2020 | 10588 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2022 | 5313 | 0.020 |
Why?
|
Retrospective Studies | 4 | 2023 | 81801 | 0.020 |
Why?
|
Anti-Bacterial Agents | 1 | 2009 | 7463 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2019 | 2460 | 0.020 |
Why?
|
Attitude of Health Personnel | 1 | 2004 | 3922 | 0.020 |
Why?
|
Treatment Outcome | 2 | 2014 | 65379 | 0.020 |
Why?
|
Overweight | 1 | 2020 | 2445 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 560 | 0.020 |
Why?
|
Stroke | 1 | 2011 | 9742 | 0.020 |
Why?
|
Pilot Projects | 1 | 2022 | 8731 | 0.020 |
Why?
|
Pyrimidines | 1 | 2021 | 3048 | 0.020 |
Why?
|
Research Design | 1 | 2004 | 6210 | 0.020 |
Why?
|
Eating | 1 | 2014 | 1541 | 0.020 |
Why?
|
Age Distribution | 1 | 2013 | 2877 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2024 | 5708 | 0.020 |
Why?
|
Maximum Tolerated Dose | 1 | 2010 | 890 | 0.020 |
Why?
|
Adiposity | 1 | 2017 | 1895 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2004 | 10377 | 0.020 |
Why?
|
Waist-Hip Ratio | 1 | 2008 | 520 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2012 | 18048 | 0.020 |
Why?
|
Population Surveillance | 1 | 2016 | 2598 | 0.020 |
Why?
|
Family Health | 1 | 2010 | 1255 | 0.020 |
Why?
|
Methotrexate | 1 | 2012 | 1722 | 0.020 |
Why?
|
Tumor Burden | 1 | 2011 | 1913 | 0.020 |
Why?
|
Cytokines | 1 | 2019 | 7445 | 0.010 |
Why?
|
Salvage Therapy | 1 | 2010 | 1277 | 0.010 |
Why?
|
Doxorubicin | 1 | 2010 | 2229 | 0.010 |
Why?
|
Pregnancy | 2 | 2016 | 30200 | 0.010 |
Why?
|
Causality | 1 | 2009 | 1255 | 0.010 |
Why?
|
Menopause | 1 | 2010 | 1653 | 0.010 |
Why?
|
Genetic Association Studies | 1 | 2012 | 2742 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2019 | 17135 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2022 | 26411 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2012 | 3520 | 0.010 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2016 | 4047 | 0.010 |
Why?
|
Contraceptives, Oral | 1 | 2003 | 562 | 0.010 |
Why?
|
Nurse Practitioners | 1 | 2004 | 271 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2012 | 8562 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2006 | 3438 | 0.010 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2004 | 390 | 0.010 |
Why?
|
Sample Size | 1 | 2003 | 848 | 0.010 |
Why?
|
Diet Surveys | 1 | 2003 | 1160 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2017 | 20224 | 0.010 |
Why?
|
Age of Onset | 1 | 2006 | 3345 | 0.010 |
Why?
|
Proteomics | 1 | 2012 | 3906 | 0.010 |
Why?
|
Mutation | 1 | 2023 | 30228 | 0.010 |
Why?
|
Body Composition | 1 | 2008 | 2461 | 0.010 |
Why?
|
Registries | 1 | 2014 | 8379 | 0.010 |
Why?
|
Focus Groups | 1 | 2004 | 1453 | 0.010 |
Why?
|
Boston | 1 | 2010 | 9371 | 0.010 |
Why?
|
Massachusetts | 1 | 2009 | 8902 | 0.010 |
Why?
|
Logistic Models | 1 | 2011 | 13323 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2006 | 6318 | 0.010 |
Why?
|
Signal Transduction | 1 | 2019 | 23631 | 0.010 |
Why?
|
Attitude to Health | 1 | 2004 | 2025 | 0.010 |
Why?
|
Male | 3 | 2021 | 364902 | 0.010 |
Why?
|
Survival Rate | 1 | 2007 | 12870 | 0.010 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2016 | 12241 | 0.010 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2007 | 3243 | 0.010 |
Why?
|
Animals | 2 | 2014 | 169337 | 0.010 |
Why?
|
Health Behavior | 1 | 2004 | 2647 | 0.010 |
Why?
|
Health Promotion | 1 | 2004 | 2209 | 0.010 |
Why?
|
Internet | 1 | 2004 | 3107 | 0.010 |
Why?
|
Mass Screening | 1 | 2004 | 5451 | 0.000 |
Why?
|
Predictive Value of Tests | 1 | 2004 | 15455 | 0.000 |
Why?
|
Primary Health Care | 1 | 2004 | 4748 | 0.000 |
Why?
|
Physicians | 1 | 2004 | 4614 | 0.000 |
Why?
|
Aging | 1 | 2004 | 8764 | 0.000 |
Why?
|
Lung Neoplasms | 1 | 2007 | 13576 | 0.000 |
Why?
|